Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Tanya Jindal

Photo of Tanya Jindal
Title(s)Affiliate, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address550 16th Street, #001
San Francisco CA 94158
ORCID ORCID Icon0000-0001-5954-3278 Additional info
vCardDownload vCard

    Collapse Overview 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer. Oncologist. 2026 Jan 17; 31(2). Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC. PMID: 41467749; PMCID: PMC12861977.
      View in: PubMed   Mentions:
    2. Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with Immunotherapy. Clin Genitourin Cancer. 2026 Feb; 24(1):102483. Grier AL, Jang A, Zhong JY, Kumar HLS, Jindal T, Calaway A, Jia AY, Fu P, Bukavina L, Ghandour R, Shoag JE, Vince R, Rao S, Sheng I, Mendiratta P, Brown JR, Gupta S, Garcia JA, Barata PC. PMID: 41530040.
      View in: PubMed   Mentions:
    3. Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. Oncologist. 2025 Nov 11; 30(11). Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR. PMID: 41124032; PMCID: PMC12622373.
      View in: PubMed   Mentions:
    4. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. Oncologist. 2025 Nov 11; 30(11). Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. PMID: 41056445; PMCID: PMC12605803.
      View in: PubMed   Mentions:
    5. Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. Urol Oncol. 2026 Jan; 44(1):65.e1-65.e11. Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. PMID: 41152111.
      View in: PubMed   Mentions:
    6. Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer Med. 2025 Oct; 14(19):e71284. Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. PMID: 41031719; PMCID: PMC12486332.
      View in: PubMed   Mentions:
    7. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol. 2025 Sep 14. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. PMID: 40954009.
      View in: PubMed   Mentions:    Fields:    
    8. REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens. Oncologist. 2025 Jun 04; 30(6). Zhong J, Jang A, Abuqayas B, Basu A, Benjamin DJ, Bhatlapenumarthi V, Bilen MA, Buch D, Chang M, Chin E, Darabi S, Dhanikonda N, Ghatalia P, Grigg CM, Grier AL, Jindal T, Jung J, Kilari D, Kumar HLS, Lee S, Neelands B, Pandya C, Pawalek J, Staggers J, Yildirim A, Zakharia Y, Zarrabi KK, Zimmerman M, Sledge G, Spetzler D, Elliott A, McKay RR, Barata PC. PMID: 40536267; PMCID: PMC12204391.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes. Clin Genitourin Cancer. 2025 Aug; 23(4):102356. Bakaloudi DR, Talukder R, Enright T, Leary JB, Makrakis D, Diamantopoulos LN, Hobeika C, Thomas VM, Swami U, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Latchford C, Jindal T, Koshkin VS, Murgic J, Miletic M, Frobe A, Johnson J, Zakharia Y, Alva A, Nguyen CB, Hui G, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Barrera RM, Marmolejo D, McKay RR, Stewart TF, Barata P, Epstein IB, Bellmunt J, Yu EY, Raychaudhuri R, Nadal R, Vakar-Lopez F, Gupta S, Wright JL, Khaki AR, Grivas P. PMID: 40378559.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol. 2025 Apr; 8(2):258-262. Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. PMID: 39709257.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2025 Feb; 23(1):102284. Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. PMID: 39798390.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Dec; 22(6):102198. Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgic J, Miletic M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. PMID: 39241315.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    14. CRE24-034: Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma With Pembrolizumab-Based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-Institutional Case Series. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5). Jang A, Jindal T, Calaway AC, Shoag JE, Koshkin VS, Barata PC. PMID: 38579747.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. JCO Precis Oncol. 2024 Apr; 8:e2300567. Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ. PMID: 38579192; PMCID: PMC11018169.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    16. Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series. Clin Genitourin Cancer. 2024 04; 22(2):315-321. Shipp C, Jindal T, Chou J, Friedlander TW, Koshkin VS, Kumar V. PMID: 38114390; PMCID: PMC12172690.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Clin Genitourin Cancer. 2023 10; 21(5):584-593. Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, Agarwal N, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Korolewicz J, Jindal T, Koshkin VS, Murgic J, Miletic M, Frobe A, Johnson J, Zakharia Y, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Carballeira CC, Barrera RM, Marmorejo D, McKay RR, Stewart T, Gupta S, Ruplin AT, Yu EY, Khaki AR, Grivas P. PMID: 37414620; PMCID: PMC11289267.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    18. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions: 7  
    20. Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2023 04; 21(2):286-294. Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. PMID: 36481176.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    21. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 12; 20(6):558-567. Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. PMID: 36155169; PMCID: PMC10233855.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 9  
    23. Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. Clin Genitourin Cancer. 2022 04; 20(2):189-194. Jindal T, Chou J, Friedlander T, Barata PC, Koshkin VS. PMID: 34998700.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022 Mar 15; 128(6):1194-1205. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. PMID: 34882781.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    Tanya's Networks
    Concepts (60)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (39)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.